PLAT and papilloma: Of the remaining compounds evaluated, CA significantly inhibited TPA promotion by 49% (5.38 papillomas per mouse; p < 0.05, Mann-Whitney U test) when compared to TPA-only group but this was not significantly different compared to the group pretreated with UA.